Abstract
Currently, there are no standardized guidelines on the need for and frequency of anti-relapse therapy in children with chronic secondary pyelonephritis.Purpose. To assess the diagnostic value of urinary neutrophil gelatinase-associated lipocalin (NGAL) measured as a ratio to urinary creatinine (NGAL/Cr), in predicting recurrence rates of chronic secondary pyelonephritis in children.Material and methods. The study included 158 children aged 2 to 14 years with chronic secondary pyelonephritis, comprising 130 girls (82.3%) and 28 boys (17.7%). Children were divided into groups based on the presence and scheme of anti-relapse therapy (furazidine and/or phytopreparation BNO 1045). This article continues the authors’ research previously published in 2019, 2020, and 2023.Results. A pre-treatment urinary NGAL/Cr level above 12 ng/mg in patients with recurrent secondary pyelonephritis allowed prediction of disease recurrence and supported the need for anti-relapse therapy. Adding the phytopreparation BNO 1045 to anti-relapse therapy for one month following a two-week furazidine course extended the relapse-free period from 13 to 16 months and reduced the recurrence risk by 1.9 times with therapy administered annually. Implementing this anti-relapse therapy every six months increased the median relapse-free period to 22 months, reducing recurrence risk by over fourfold.Conclusion. The study demonstrates the predictive value of urinary NGAL/Cr levels before the initiation of antibacterial therapy, allowing assessment of relapse risk in secondary pyelonephritis. The findings support the necessity of anti-relapse therapy in children with chronic secondary pyelonephritis. Optimal remission extension was achieved with a combination therapy of furazidine and phytopreparation BNO 1045.

This publication has 15 references indexed in Scilit: